Myeloid

AIDA - Acute Promyelocytic Leukaemia (APML) Protocol V2.0

Asciminib Chronic Myeloid Leukaemia V1.1

ATGAM (Anti-thymocyte Globulin - Equine) & Ciclosporin Aplastic Anaemia Protocol V1.0

Alemtuzumab (Campath®) & IV Cladribine (Leustat) T-Cell Prolymphocytic Leukaemia (TPLL) V1.0

Azacitidine (Subcut) v1.1

Azacitidine and Venetoclax AML Protocol V1.0

Blinatumomab (Blincyto®) B-Precursor Acute Lymphoblastic Leukaemia Protocol V1.0

DA (Daunorubicin and Cytarabine) Acute Myeloid Leukaemia (AML) Protocol V1.2

DA & Gemtuzumab Ozogamycin (Mylotarg) Acute Myeloid Leukaemia (AML) V2.1

Flag IDA Acute Myeloid Leukaemia (AML) V1.2

Gilteritinib Relapsed or Refractory Acute Myeloid Leukaemia (AML) V1.0

High Dose Cytarabine Acute Myeloid Leukaemia V1.1

Hyper-CVAD (+/-R) / MA (+/-R) AGGRESSIVE LYMPHOMA / ALL V1.0

Imatinib Chronic Myeloid Leukaemia Protocol V1.0

Induction Phase 1 (25-60 Years) Acute Lymphoblastic Leukaemia (ALL) V1.1

Inotuzumab Ozogamycin Relapsed / Refractory Acute Lymphoblastic Leukaemia V2.0

Low dose Cytarabine (Ara-C) Protocol V2.0

Midostaurin Acute Myeloid Leukaemia (AML) V2.0

Midostaurin Aggressive systemic mastocytosis, systemic mastocytosis with associated haematological neoplasm or mast cell leukaemia in adults V1.0

Nilotinib Chronic Myeloid Leukaemia Protocol V2.0

Oral or Subcutaneous Weekly Methotrexate Large Granular Lymphocytic Leukaemia And Cutaneous T-cell Lymphoma V1.0

Ponatinib Chronic Myeloid Leukaemia Protocol V1.0

Vyxeos (Liposomal Cytarabine and Daunorubicin) Protocol V2.0